Skip to main content
Springer Nature Link
Log in

Varespladib trial terminated, increased MI risk

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks; the trial was funded by Anthera Pharmaceuticals.

Reference

  • Nicholls SJ, et al. Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial. JAMA: the Journal of the American Medical Association : [11 pages], 18 Nov 2013. Available from: URL: http://dx.doi.org/10.1001/jama.2013.282836

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Varespladib trial terminated, increased MI risk. Reactions Weekly 1484, 1 (2014). https://doi.org/10.1007/s40278-014-8217-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-8217-5